- Home
- JFU vs EDSA Comparison
JFU vs EDSA Comparison
Compare JFU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- EDSA
- Stock Information
- Founded
- JFU 2006
- EDSA 2015
- Country
- JFU China
- EDSA Canada
- Employees
- JFU N/A
- EDSA N/A
- Industry
- JFU Finance: Consumer Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- EDSA Health Care
- Exchange
- JFU Nasdaq
- EDSA Nasdaq
- Market Cap
- JFU 17.1M
- EDSA 13.8M
- IPO Year
- JFU 2019
- EDSA N/A
- Fundamental
- Price
- JFU $1.40
- EDSA $2.05
- Analyst Decision
- JFU
- EDSA Strong Buy
- Analyst Count
- JFU 0
- EDSA 2
- Target Price
- JFU N/A
- EDSA $13.00
- AVG Volume (30 Days)
- JFU 2.9K
- EDSA 33.4K
- Earning Date
- JFU 01-01-0001
- EDSA 08-08-2025
- Dividend Yield
- JFU N/A
- EDSA N/A
- EPS Growth
- JFU N/A
- EDSA N/A
- EPS
- JFU 0.09
- EDSA N/A
- Revenue
- JFU $40,614,155.00
- EDSA N/A
- Revenue This Year
- JFU N/A
- EDSA N/A
- Revenue Next Year
- JFU N/A
- EDSA N/A
- P/E Ratio
- JFU $15.08
- EDSA N/A
- Revenue Growth
- JFU N/A
- EDSA N/A
- 52 Week Low
- JFU $1.01
- EDSA $1.55
- 52 Week High
- JFU $3.60
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- JFU 50.23
- EDSA 52.89
- Support Level
- JFU $1.36
- EDSA $1.91
- Resistance Level
- JFU $1.48
- EDSA $2.14
- Average True Range (ATR)
- JFU 0.07
- EDSA 0.12
- MACD
- JFU -0.01
- EDSA 0.02
- Stochastic Oscillator
- JFU 21.13
- EDSA 64.52
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.